Related Experiment Videos
Amodiaquine-induced fulminant hepatitis
J Bernuau1, D Larrey, B Campillo
1Unité de Recherches de Physiopathologie Hépatique (INSERM U 24), Hôpital Beaujon, Clichy, France.
Journal of Hepatology
|February 1, 1988
Summary
Amodiaquine use for malaria prophylaxis can lead to severe hepatitis. Prolonged drug administration after jaundice onset increases mortality risk, highlighting the need for prompt interruption.
Area of Science:
- Hepatology
- Pharmacology
- Infectious Diseases
Background:
- Amodiaquine is an antimalarial drug used for malaria prophylaxis.
- Fulminant hepatitis is a rare but severe liver condition.
Observation:
- Three patients developed fulminant hepatitis after ingesting amodiaquine for malaria prophylaxis.
- Drug administration continued for weeks after jaundice onset in all three cases.
Findings:
- Two of the three patients died from fulminant hepatitis.
- One patient survived after emergency liver transplantation.
- Protracted amodiaquine use, especially when jaundice is present, is associated with poor outcomes.
Implications:
- This study highlights the critical need to promptly discontinue amodiaquine upon the appearance of jaundice.
- Physicians should be vigilant for amodiaquine-induced hepatotoxicity during malaria prophylaxis.
- Early recognition and intervention are crucial for improving survival rates in amodiaquine-induced liver injury.